ArticleBrain structure & function2025
Investigating the therapeutic potential of transcranial direct current stimulation in an experimental Parkinson's model through glutamate pathway.
Article in Brain structure & function, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The study’s objective was to look into the glutamate-mediated therapeutic effects of tDCS, which is known to modulate motor cortical plasticity and is thought to be a potential alternative treatment for Parkinson’s disease (PD), in 6-hydroxydopamine (6-OHDA) lesion rats with behavioral changes. Following tDCS application (0.5 mA anodal and cathodal tDCS, 30 min/day, 5 days/week, starting 7 days after the PD lesion) in PD animals, the effects of treatment on motor and non-motor behaviors as well as the glutamatergic pathway were determined. Four groups were conducted: Sham, PD, PD + A-tDCS (anodal stimulation) and PD + C-tDCS (cathodal stimulation). Apomorphine-induced rotation test, cylinder test, open field and new object recognition tests were performed. Glutamate, NMDA and EAAT2 levels were evaluated in the total hippocampus, prefrontal cortex and substantia nigra tissues. We found that tDCS treatment, regardless of anodal or cathodal, significantly attenuated 6-OHDA-induced motor activity deficits, as measured in open field test, apomorphine-induced rotations, and cylinder test performances, and was also effective in new object recognition memory. Glutamate and NMDA levels increased in the hippocampus, prefrontal cortex and substantia nigra tissues, while EAAT2 levels decreased in the PD group. tDCS application was significantly alleviated the effects of 6-OHDA. These results suggest that tDCS application can improve the aggravation of locomotor activity and learning performance, and exhibit neuroprotective effects through glutamate, NMDA and EAAT2 in PD rat model.
Indexed as
Identifiers
41283910What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.